Evidence map›Paper›PMID 42006373›Full record

ArticleiScience2026

UHRF1 drives subtype-independent aggressiveness and immune evasion in small cell lung cancer through PRC2 interactions.

Yijun Gu, Jamie-Jean De La Torre, Yasamin Fazeli, J Mateo Valenzuela, Frederick Guzman, Roberto Tinoco, Claudia A Benavente

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yijun GuDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA.
Jamie-Jean De La TorreDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA.
Yasamin FazeliDepartment of Developmental and Cell Biology, University of California, Irvine, Irvine, CA 92697, USA.
J Mateo ValenzuelaDepartment of Developmental and Cell Biology, University of California, Irvine, Irvine, CA 92697, USA.
Frederick GuzmanDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA.
Roberto TinocoDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92697, USA.
Claudia A BenaventeDepartment of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA 92697, USA.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) carcinoma characterized by early metastasis and an immune-cold microenvironment. We show that UHRF1, a chromatin-associated effector of RB1/E2F signaling, promotes SCLC growth and metastasis across major molecular subtypes. Using human SCLC cell lines, orthotopic and intracardiac xenografts, and genetically engineered mouse models, we found that loss of UHRF1 reduces proliferation, invasion, tumor burden, and metastasis while reprogramming tumors away from NE states toward an inflamed transcriptional program. UHRF1-deficient tumors upregulate chemokines and exhibit increased infiltration of CD8

Indexed as

biological sciencescancerepigeneticsimmunology

Identifiers

PMID42006373
PMCPMC13090669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.